DiaGenic ASA: Report from fourth quarter 2011

OSLO, Norway--(BUSINESS WIRE)--Regulatory News: First mover in blood based CNS biomarkers The interim report for the fourth quarter 2011 was approved by the Board of Directors on 13 February 2011. Please find the interim report and presentation attached. Highlights from the report: MCItect®: The first blood based test for early Alzheimer disease (AD) As the world’s first blood-based prodromal AD gene expression markers, DiaGenic has demonstrated that MCI patients converting to AD within two year

Feed Date: 
February 14, 2012